# US 2010/0136626 A1 · Production and Use of Novel Peptide-Based Agents for Use with Bi-Specific Antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0136626 A1
- Document ID: US20100136626A1
- Status: Published application
- Kind: A1
- Application number: 12/582,009
- Filed: 2009-10-20
- Published: 2010-06-03
- Earliest claimed: 1998-06-22
- Assignees: Immunomedics, Inc.
- Inventors: Hans J. Hansen; Gary L. Griffiths; Shui-on Leung; William J. McBride; Zhengxing Qu
- Web page: https://patentgrep.com/patent/US20100136626A1

## CPC

- C07K 16/468: {Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies}
- A61K 47/6863: {the tumour determinant being from stomach or intestines cancer cell}
- A61K 47/6899: {Antibody-Directed Enzyme Prodrug Therapy [ADEPT]}
- A61K 51/1048: {the tumor cell determinant being a carcino embryonic antigen}
- A61K 51/1063: {the tumor cell being from stomach or intestines}
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- C07K 16/18: against material from animals or humans
- C07K 16/30: from tumour cells
- C07K 16/3007: {Carcino-embryonic Antigens}
- C07K 16/3046: {Stomach, Intestines}
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/12: isolated from milk
- C07K 2317/13: isolated from plants
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/55: Fab or Fab'
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES

## Abstract

The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that is reactive against a targeted tissue and at least one other arm that is reactive against a targetable conjugate. The targetable conjugate encompasses a hapten to which antibodies have been prepared. In preferred embodiments, the hapten is histamine-succinyl-glycine (HSG). In more preferred embodiments, the at least one arm comprises the CDR sequences of the HSG-binding 679 antibody. The targetable conjugate is attached to one or more therapeutic and/or diagnostic agents. The invention provides constructs and methods for producing the bispecific antibodies or antibody fragments, as well as methods for using them and kits comprising them.

## Claims

### Claim 1

An isolated nucleic acid encoding a 679 antibody light chain variable region amino acid sequence, wherein said 679 antibody light chain variable region amino acid sequence comprises the complementarity determining region (CDR) sequences CDR1 (KSSQSLFNSRTRKNYLG, residues 24-40 of SEQ ID NO:2), CDR2 (WASTRES, residues 56-62 of SEQ ID NO:2) and CDR3 (TQVYYLCT, residues 95-102 of SEQ ID NO:2).

### Claim 2 (depends on 1)

The isolated nucleic acid according to claim 1, wherein the nucleic acid comprises a sequence of SEQ ID NO:1.

### Claim 3 (depends on 1)

The isolated nucleic acid according to claim 1, wherein the nucleic acid encodes an amino acid sequence of SEQ ID NO:2.

### Claim 4

An isolated nucleic acid encoding a 679 antibody heavy chain variable region amino acid sequence, wherein said 679 antibody heavy chain variable region amino acid sequence comprises the CDR sequences CDR1 (IYTMS, residues 30-34 of SEQ ID NO:4), CDR2 (TLSGDGDDIYYPDSVKG, residues 49-65 of SEQ ID NO:4) and CDR3 (VRLGDWDFDV, residues 98-107 of SEQ ID NO:4).

### Claim 5 (depends on 4)

The isolated nucleic acid according to claim 4, wherein the nucleic acid comprises a sequence of SEQ ID NO:3.

### Claim 6 (depends on 4)

The isolated nucleic acid according to claim 4, wherein the nucleic acid encodes an amino acid sequence of SEQ ID NO:4.

### Claim 7

An isolated nucleic acid encoding 679 antibody light and heavy chain variable region amino acid sequences, wherein said 679 antibody light chain variable region amino acid sequence comprises the CDR sequences CDR1 (KSSQSLFNSRTRKNYLG, residues 24-40 of SEQ ID NO:2), CDR2 (WASTRES, residues 56-62 of SEQ ID NO:2) and CDR3 (TQVYYLCT, residues 95-102 of SEQ ID NO:2) and said 679 antibody heavy chain variable region amino acid sequence comprises the CDR sequences CDR1 (IYTMS, residues 30-34 of SEQ ID NO:4), CDR2 (TLSGDGDDIYYPDSVKG, residues 49-65 of SEQ ID NO:4) and CDR3 (VRLGDWDFDV, residues 98-107 of SEQ ID NO:4).

### Claim 8 (depends on 7)

The isolated nucleic acid according to claim 7, wherein the nucleic acid comprises a sequence of SEQ ID NO:5.

### Claim 9 (depends on 7)

The isolated nucleic acid according to claim 7, wherein the nucleic acid encodes an amino acid sequence of SEQ ID NO:6.

### Claim 10 (depends on 7)

The isolated nucleic acid of claim 7, wherein said isolated nucleic acid encodes a 679 antibody or antigen-binding fragment thereof.

### Claim 11 (depends on 10)

The isolated nucleic acid of claim 10, wherein said antibody or fragment thereof is a humanized or chimeric antibody or fragment thereof.

### Claim 12 (depends on 10)

The isolated nucleic acid of claim 10, wherein said antibody fragment is selected from the group consisting of F(ab′)2, F(ab)2, Fab′, Fab, Fv and scFv fragments.

### Claim 13 (depends on 10)

The isolated nucleic acid of claim 10, wherein the antibody or antibody fragment is a fusion protein.

### Claim 14 (depends on 13)

The isolated nucleic acid of claim 13, wherein the antibody or antibody fragment is a bispecific antibody or antibody fragment.

### Claim 15 (depends on 14)

The isolated nucleic acid of claim 14, wherein the bispecific antibody or antibody fragment comprises at least one arm which binds to a targeted tissue.

### Claim 16 (depends on 15)

The isolated nucleic acid of claim 15, wherein the targeted tissue is a cancer.

### Claim 17 (depends on 15)

The isolated nucleic acid of claim 15, wherein the at least one arm that binds to a targeted tissue binds to an antigen selected from CSAp and CEA.

### Claim 18 (depends on 17)

The isolated nucleic acid of claim 17, wherein the at least one arm that binds to a targeted tissue is a murine, humanized or chimeric MN-14 or Mu-9 antibody.

### Claim 19 (depends on 10)

An expression vector comprising an isolated nucleic acid according to claim 10.

### Claim 20 (depends on 19)

A transformed cell line comprising an expression vector according to claim 19.

### Claim 21 (depends on 20)

A method of producing an HSG-binding antibody or antibody fragment comprising:
a) obtaining a transformed cell line according to claim 20; and
b) culturing the cell line to express an HSG-binding antibody or antibody fragment.

### Claim 22 (depends on 21)

The method of claim 21, wherein the HSG-binding antibody or antibody fragment is a fusion protein.

### Claim 23 (depends on 22)

The method of claim 22, wherein the fusion protein is a bispecific antibody or antibody fragment.
